Georgina Cox1, Kalinka Koteva1, Gerard D Wright2. 1. Department of Biochemistry and Biomedical Sciences, M. G. DeGroote Institute for Infectious Disease Research, McMaster University, 1280 Main St W, Hamilton, Ontario L8S 4K1, Canada. 2. Department of Biochemistry and Biomedical Sciences, M. G. DeGroote Institute for Infectious Disease Research, McMaster University, 1280 Main St W, Hamilton, Ontario L8S 4K1, Canada wrightge@mcmaster.ca.
Abstract
OBJECTIVES: An orthogonal approach taken towards novel antibacterial drug discovery involves the identification of small molecules that potentiate or enhance the activity of existing antibacterial agents. This study aimed to identify natural-product rifampicin adjuvants in the intrinsically resistant organism Escherichia coli. METHODS: E. coli BW25113 was screened against 1120 actinomycete fermentation extracts in the presence of subinhibitory (2 mg/L) concentrations of rifampicin. The active molecule exhibiting the greatest rifampicin potentiation was isolated using activity-guided methods and identified using mass and NMR spectroscopy. Susceptibility testing and biochemical assays were used to determine the mechanism of antibiotic potentiation. RESULTS: The anthracycline Antibiotic 301A(1) was isolated from the fermentation broth of a strain of Streptomyces (WAC450); the molecule was shown to be highly synergistic with rifampicin (fractional inhibitory concentration index = 0.156) and moderately synergistic with linezolid (FIC index = 0.25) in both E. coli and Acinetobacter baumannii. Activity was associated with inhibition of efflux and the synergistic phenotype was lost when tested against E. coli harbouring mutations within the rpoB gene. Structure-activity relationship studies revealed that other anthracyclines do not synergize with rifampicin and removal of the sugar moiety of Antibiotic 301A(1) abolishes activity. CONCLUSIONS: Screening only a subsection of our natural product library identified a small-molecule antibiotic adjuvant capable of sensitizing Gram-negative bacteria to antibiotics to which they are ordinarily intrinsically resistant. This result demonstrates the great potential of this approach in expanding antibiotic effectiveness in the face of the growing challenge of resistance in Gram-negatives.
OBJECTIVES: An orthogonal approach taken towards novel antibacterial drug discovery involves the identification of small molecules that potentiate or enhance the activity of existing antibacterial agents. This study aimed to identify natural-product rifampicin adjuvants in the intrinsically resistant organism Escherichia coli. METHODS:E. coli BW25113 was screened against 1120 actinomycete fermentation extracts in the presence of subinhibitory (2 mg/L) concentrations of rifampicin. The active molecule exhibiting the greatest rifampicin potentiation was isolated using activity-guided methods and identified using mass and NMR spectroscopy. Susceptibility testing and biochemical assays were used to determine the mechanism of antibiotic potentiation. RESULTS: The anthracycline Antibiotic 301A(1) was isolated from the fermentation broth of a strain of Streptomyces (WAC450); the molecule was shown to be highly synergistic with rifampicin (fractional inhibitory concentration index = 0.156) and moderately synergistic with linezolid (FIC index = 0.25) in both E. coli and Acinetobacter baumannii. Activity was associated with inhibition of efflux and the synergistic phenotype was lost when tested against E. coli harbouring mutations within the rpoB gene. Structure-activity relationship studies revealed that other anthracyclines do not synergize with rifampicin and removal of the sugar moiety of Antibiotic 301A(1) abolishes activity. CONCLUSIONS: Screening only a subsection of our natural product library identified a small-molecule antibiotic adjuvant capable of sensitizing Gram-negative bacteria to antibiotics to which they are ordinarily intrinsically resistant. This result demonstrates the great potential of this approach in expanding antibiotic effectiveness in the face of the growing challenge of resistance in Gram-negatives.
Authors: Anja Schumacher; Rainer Trittler; Jürgen A Bohnert; Klaus Kümmerer; Jean-Marie Pagès; Winfried V Kern Journal: J Antimicrob Chemother Date: 2006-09-13 Impact factor: 5.790
Authors: Alexander J Kallen; Yi Mu; Sandra Bulens; Arthur Reingold; Susan Petit; Ken Gershman; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; William Schaffner; Priti R Patel; Scott K Fridkin Journal: JAMA Date: 2010-08-11 Impact factor: 56.272
Authors: J Ruben Morones-Ramirez; Jonathan A Winkler; Catherine S Spina; James J Collins Journal: Sci Transl Med Date: 2013-06-19 Impact factor: 17.956
Authors: Alicia Fajardo; Nadia Martínez-Martín; María Mercadillo; Juan C Galán; Bart Ghysels; Sandra Matthijs; Pierre Cornelis; Lutz Wiehlmann; Burkhard Tümmler; Fernando Baquero; José L Martínez Journal: PLoS One Date: 2008-02-20 Impact factor: 3.240
Authors: Ganesh Krishnamoorthy; David Wolloscheck; Jon W Weeks; Cameron Croft; Valentin V Rybenkov; Helen I Zgurskaya Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191
Authors: David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker Journal: Clin Microbiol Rev Date: 2020-05-13 Impact factor: 26.132
Authors: Daniel V Zurawski; Alexandria A Reinhart; Yonas A Alamneh; Michael J Pucci; Yuanzheng Si; Rania Abu-Taleb; Jonathan P Shearer; Samandra T Demons; Stuart D Tyner; Troy Lister Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: Divakara S S M Uppu; Mohini M Konai; Paramita Sarkar; Sandip Samaddar; Isabel C M Fensterseifer; Celio Farias-Junior; Paramanandam Krishnamoorthy; Bibek R Shome; Octávio L Franco; Jayanta Haldar Journal: PLoS One Date: 2017-08-24 Impact factor: 3.240